Citius Pharmaceuticals, Inc.
CTXRDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
CTXR Earnings Report
EPS Est: $-0.36 | FQ end 2026-06
How CTXR's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Monad 1 | Phase 2 | Hemorrhoids | - | - |
Hydrocortisone acetate and lidocaine hydrochloride | Phase 2 | Hemorrhoids | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Citius Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Citius Pharmaceuticals, Inc.'s (CTXR) pipeline across Phase 2. Its lead program is Monad 1 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Citius Pharmaceuticals, Inc.'s next FDA catalyst?→
Citius Pharmaceuticals, Inc.'s (CTXR) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CTXR biotech catalysts?→
Add CTXR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Citius Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.